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Abstract
Background: Neuroinflammation is an important contributor to the development of neurodegenerative diseases,
including Alzheimer’s disease. Thus, there is a keen interest in identifying compounds, especially from herbal
sources, that can inhibit neuroinflammation. Amyloid-b (Ab) is a major component of the amyloid plaques present
in the brains of Alzheimer’s disease patients. Here, we examined whether sinomenine, present in a Chinese
medicinal plant, prevents oligomeric Ab-induced microglial activation and confers protection against neurotoxicity.
Methods: Oligomeric amyloid-b was prepared from Ab(1-42). Intracellular reactive oxygen species production was
determined using the dye 2’,7’-dichlorodihydrofluorescin diacetate. Nitric oxide level was assessed using the Griess
reagent. Flow cytometry was used to examine the levels of inflammatory molecules. BV2-conditioned medium was
used to treat hippocampal cell line (HT22) and primary hippocampal cells in indirect toxicity experiments. Toxicity
was assessed using MTT reduction and TUNEL assays.
Results: We found that sinomenine prevents the oligomeric Ab-induced increase in levels of reactive oxygen
species and nitric oxide in BV2 microglial cells. In addition, sinomenine reduces levels of Ab-induced inflammatory
molecules. Furthermore, sinomenine protects hippocampal HT22 cells as well as primary hippocampal cells from
indirect toxicity mediated by Ab-treated microglial cells, but has no effect on Ab-induced direct toxicity to HT22
cells. Finally, we found that conditioned medium from Ab-treated BV2 cells contains increased levels of nitric oxide
and inflammatory molecules, but the levels of these molecules are reduced by sinomenine.
Conclusions: Sinomenine prevents oligomeric Ab-induced microglial activation, and confers protection against
indirect neurotoxicity to hippocampal cells. These results raise the possibility that sinomenine may have therapeutic
potential for the treatment of Alzheimer’s diseases as well as other diseases that involve neuroinflammation.
Background
Alzheimer’s disease (AD) is a devastating neurodegenera-
tive disorder that eventually leads to severe cognitive
impairment. Although AD is typically a late onset disease,
in a small number of familial cases it occurs early in life.
Extracellular amyloid plaques and intracellular neurofi-
brillary tangles are the pathological hallmarks of AD.
Amyloid-b (Ab) is a major component of the plaques. Ab
is produced by processing of amyloid precursor protein,
and plays important roles in the pathogenesis of AD. Ab
exists in several forms, including oligomeric forms. Oli-
gomeric Ab is thought to play an important role in the
development of the disease [1,2]. Several studies have
shown that oligomeric Ab causes neuronal cell death,
impairment in synaptic plasticity and memory deficits
[e.g. [3-6]].
The available evidence suggests that neuroinflammation
contributes to the development of neurodegenerative dis-
eases, including AD [7,8]. Microglia are the resident
immune cells in the brain. They are normally in a resting
state, but they become activated in response to pathogens,
toxins or cellular damage. Microglia are found in close
association with the neuritic plaques in AD brain [9], and
Ab-induced inflammatory responses mediated by micro-
glia are thought to contribute to neuronal toxicity [10].
Treatment of microglia with Ab leads to release of inflam-
matory and toxic factors including reactive oxygen species
(ROS) and nitric oxide (NO) [11,12], which may lead to
neuronal cell damage and eventual death. Ab inhibits
long-term potentiation (LTP), which is considered a
promising cellular mechanism for memory formation.
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glia [13]. Thus, in addition to direct neuronal cell death,
Ab causes indirect neuronal cell death due to neuroin-
flammation, and inhibits synaptic plasticity.
Considering the available supporting literature regard-
ing the role of microglial activation in neurodegenerative
disorders, there is keen interest in identifying compounds
from natural sources that can reduce or prevent neuroin-
flammation, and which thus could be beneficial in neuro-
degenerative diseases, including AD. Sinomenine is an
alkaloid isolated from Sinomenium acutum,aC h i n e s e
medicinal plant. It is a dextrorotatory morphinan analog
which shares structural similarity with morphine, and
weakly binds to the opioid μ-receptor [14]. Qian and
colleagues [15] have shown that sinomenine protects
dopaminergic neurons against lipopolysaccharide (LPS)-
induced cell death in neuron-glia cultures. NADPH
oxidase (PHOX) activity is involved in the protective
effects of sinomenine. In addition, this compound confers
protection against 1-methyl-4-phenylpyridinium (MPP
+)-induced cell death. Wang and colleagues [16] found
that sinomenine reduces advanced glycation end pro-
ducts-induced increases in the levels of cytokines in ret-
inal microglial cells. Furthermore, this compound shows
beneficial effects in rheumatoid arthritis and mesangial
proliferative nephritis [17], inhibits morphine withdrawal
symptoms [18], and shows protective effects against cold
ischemia/reperfusion injury [19]. In this study, we have
examined the effects of sinomenine on oligomeric
Ab-induced microglial activation. In addition, we have
investigated the protective effects of this compound on
neuronal toxicity caused by Ab.
Methods
Preparation of oligomeric amyloid beta
Oligomeric amyloid-b (Ab-derived diffusible ligands,
ADDL) was prepared using amyloid-b 1-42 peptide
(American Peptide) as described previously [20] with
minor modifications. The peptide was dissolved in
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP, Fluka), ali-
quoted, dried in fume hood a n ds t o r e da t- 8 0 ° C .T h e
peptide film was dissolved in DMSO to 5 mM concentra-
tion and further diluted in phosphate-buffered saline
(PBS) to make a 100 μM solution. This preparation was
incubated at 4°C for 24 h. To remove insoluble material,
the preparation was centrifuged at 14,000 g for 10 min at
4°C. The soluble fraction (ADDL) was stored at -80°C
until use. Protein concentration was determined using
BCA reagent with bovine serum albumin as standard.
ADDL was used at a 2 μM final concentration [21].
Cell culture and treatments
Sinomenine (Sigma-Aldrich) was dissolved in DMSO
and diluted to different concentrations in DMEM such
that the final DMSO concentration was 0.1%. BV2
microglial cells were obtained from Dr. A. Basu of our
Centre and cultured in DMEM with 10% fetal bovine
serum (FBS). The cells were serum starved for 4-8 h
before treatment. The control cultures received vehicle
for ADDL. For the analysis of reactive oxygen species
and nitric oxide, and for assaying the levels of inflamma-
tory molecules described under “sinomenine reduces A-
beta-induced increases in inflammatory molecules”, cells
were cultured in 24-well plates (3.5 × 10
4cells per well).
After serum starvation, BV2 cells were treated with
sinomenine for 1.5 h, then with ADDL for 12 h, co-inci-
dent with ADDL treatment of a sister culture. For “pre-
treatment condition” ADDL and sinomenine treatment
was done as described above, whereas for “simultaneous
addition”, ADDL and sinomenine were added to the cul-
ture at the same time. After treatment, samples were
used for different assays. For the indirect toxicity experi-
ments and for the analysis of NO and inflammatory
molecules in the BV2 conditioned media, BV2 cells
g r o w ni n2 4 - w e l lp l a t e s( 3×1 0
4 cells per well) were
treated with sinomenine for 1.5 h, then with ADDL for
6 h, co-incident with ADDL treatment of a sister cul-
ture. After treatment, the cells were washed and fresh
medium was added without ADDL or sinomenine. The
conditioned medium was collected after a 12 h period
and then centrifuged to obtain cell-free supernatant. In
all cases sinomenine was present throughout ADDL
treatment. Where sinomenine alone was used, the cul-
tures were treated with sinomenine (without ADDL)
similar to the sinomenine + ADDL condition.
Hippocampal HT22 cells were a kind gift from
Dr. D. Schubert, The Salk Institute, La Jolla, California.
The cells were cultured in DMEM with 10% FBS [in a
96-well plate (5 × 10
3 cells per well) for MTT assay or
in poly-D-lysine-coated 4-well chamber slide (1 × 10
4
cells per well) for TUNEL assay]. For the indirect toxi-
city experiments, HT22 cells were serum-starved for
4 h and then treated with a mixture of 50% BV2-con-
ditioned medium and 50% fresh DMEM. For MTT
assay, cells were treated for 44 h (before addition of
MTT), and for the TUNEL assay, cells were treated for
48 h. For direct toxicity experiments HT22 cells were
serum-starved for 2.5 h, treated with sinomenine for
1.5 h, then treated with ADDL, co-incident with
ADDL treatment of a sister culture. Sinomenine was
present throughout the ADDL treatment. ADDL treat-
ment was for 20 h (before addition of MTT) for MTT
assay and 24 h for TUNEL assay.
For primary hippocampal cultures, Sprague Dawley
pregnant female rats were sacrificed according to a pro-
tocol approved by the Institutional Animal Ethics Com-
mittee and hippocampal cultures were prepared from
E18-E20 embryos as described previously [21] with
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and triturated to obtain dissociated cells which were then
seeded in 90 mm dishes in DME\F12 medium with 10%
FBS. After 16-20 h, the medium was replaced with
Neurobasal medium containing B27 supplement, gluta-
max (all from Invitrogen) and glutamic acid (Sigma-
Aldrich). After 4 days in vitro (DIV), cells were detached
from the plates and seeded in 8-well chamber slides (6 ×
10
4 cells per well) in 50% fresh Neurobasal maintenance
medium (Neurobasal medium containing B27 supple-
ment and glutamax) mixed with 50% neuronal condi-
tioned medium. Ara C (5 μM; Sigma-Aldrich) was added
to reduce glial cell proliferation. Fifty percent of the med-
ium was replaced every 2 days with Neurobasal mainte-
nance medium, and cultures were used for treatment on
DIV 8-9. For indirect toxicity experiments, cells were
treated for 24 h with 50% BV2-conditioned medium that
was mixed with 50% fresh Neurobasal maintenance
medium.
Reactive oxygen species assay
BV2 cells were treated under different conditions, and
the level of intracellular ROS was measured fluorimetri-
cally using the dye 2’,7’-dichlorodihydrofluorescin diace-
tate (DCFDA; Sigma-Aldrich) as described previously
[21,22]. The cells were incubated with DMEM containing
5 μM DCFDA for 1 h at 37°C, washed with PBS and
lysed in lysis buffer (10 mM Tris pH 7.9, 150 mM NaCl,
1 mM EDTA, 0.2 mM EGTA, 0.2 mM NaVO3, 0.5% NP-
40 and 1% Triton X-100). The lysate was centrifuged at
10,000 g for 15 min. A 10-μl aliquot of supernatant was
mixed with 90 μl of PBS in a 96-well black plate and
fluorescence was measured using a Varioskan Flash mul-
timode Reader (Thermo Electron Corporation, Finland)
at an excitation wavelength of 485 nm and an emission
wavelength of 530 nm. The readings obtained were nor-
malized with the amount of protein in each sample. Data
are expressed as a percentage of control cultures.
Nitric oxide assay
After different treatments of BV2 cells, released nitric
oxide was measured in the culture medium using Griess
reagent (Sigma-Aldrich). A 100-μl aliquot of cell-free cul-
ture medium was incubated with 100 μl of Griess reagent
in the dark at room temperature for 15 min. The intensity
of color developed was measured at 540 nm using a
Benchmark Plus 96-well ELISA plate Reader (BioRad).
Data are expressed as a percentage of control samples.
Cytokine bead array assay
BV2 cells were treated under different conditions, and
the levels of inflammatory molecules were measured in
cell free culture medium using a Mouse Inflammation
cytokine bead array kit (Becton Dickinson) as described
previously [23] with minor modifications. Briefly, a 30-μl
bead mix was incubated with an aliquot of cell-free cul-
ture medium and 30 μl of phycoerythrin detection
reagent for 2 h at room temperature in the dark. The
beads were then washed with wash buffer (provided with
the kit), re-suspended in 300 μlo ft h ew a s hb u f f e ra n d
analyzed in FACS Calibur using Cell Quest Pro Software
and BD CBA software (Becton Dickinson, San Diego,
CA). The standard curve was prepared according to the
kit’s manual. Data are expressed as fold relative to
control.
MTT assay
Cell viability of HT22 cells was assessed using 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT, Sigma-Aldrich) assay. After treatment, MTT
reagent was added to the wells, incubated for 4 h, and the
samples were processed for MTT assay as described pre-
viously [21]. The absorbance was measured at 570 nm.
The mean of readings of triplicate wells was taken as one
value. The OD value for the control cultures was consid-
ered as 100% viability and viability in other samples is
expressed as a percentage of viability in the control
cultures.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) assay
After treatments, cells were fixed and processed for
TUNEL assay as described previously [21]. The total num-
ber of DAPI (4’6 diamidino-2-phenylindole)-stained or
TUNEL-positive cells, in 5 different frames, were counted.
The average number of cells (DAPI-stained) per frame in
experiments ranged from 162-213.6 (control), 170.8-215.6
(ADDL) and 175.2-217 (ADDL + sinomenine) in HT22
indirect toxicity experiments, 123.4-130.2 (control), 124-
135.2 (ADDL) and 125.8-134.4 (ADDL + sinomenine) in
primary hippocampal cell indirect toxicity experiments,
and 87.4-121 (control), 81-105.6 (ADDL) and 82.2-101.8
(ADDL + sinomenine) in HT22 direct toxicity experi-
ments. Data are expressed as percent TUNEL-positive
cells.
Data analysis
Data were analyzed using a paired Student’st - t e s t .D i f -
ferences were considered significant when the p value
was less than 0.05. Data are expressed as mean ± SEM.
Results
Sinomenine inhibits amyloid-b-induced increase in level
of reactive oxygen species in microglial cells
Previous studies have shown that treatment of microglial
cells with Ab increases the level of reactive oxygen species
(ROS) [e.g. 24]. Using DCFDA, a commonly used reagent
to measure intracellular ROS [21,22], we found that
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nificant increase in the level of ROS [135.8% ± 2.56 (% con-
trol)]. We next examined whether sinomenine has any
effect on the level of ROS induced by oligomeric Ab. For
this analysis, we treated BV2 cells with ADDL or ADDL
plus different concentrations of sinomenine. Taking a clue
from previous studies [15,16], we used 10
-14 M, 10
-7 Ma n d
10
-4 M sinomenine in our experiments. We found that
whereas ADDL treatment increased the level of ROS, sino-
menine decreased ROS level induced by oligomeric Ab
(Figure 1A). Sinomenine alone at all three concentrations
had no significant effect on basal ROS levels (data not
shown). This observation is consistent with that of Wang
et al [16] who found that sinomenine does not affect the
basal level of ROS in microglial cells. All sinomenine con-
centrations tested reduced ADDL-induced increase in ROS
generation, but the 10
-4 M concentration gave the best
results. Hence, in subsequent experiments, we used this
concentration of sinomenine.
In these experiments, BV2 cells were treated with sino-
menine before addition of ADDL (Pre-treatment condi-
tion). Thus, we next asked whether simultaneous
treatment of sinomenine and ADDL has any effect on
ADDL-induced ROS generation. We found that whereas
pre-treatment with sinomenine inhibited ADDL-induced
ROS generation, simultaneous treatment with sinome-
nine did not reduce ADDL-induced ROS level (Figure
1B). Thus, pretreatment with sinomenine is required for
its effect on ADDL-induced ROS level. In subsequent
experiments, pretreatment with sinomenine was used to
examine its effects in different assays.
Sinomenine inhibits amyloid-b-induced increase in level
of nitric oxide in BV2 cells
Ab is known to increase levels of inducible nitric oxide
synthase (iNOS) in microglial cells [25,26]. Since the
induction of iNOS is associated with increased production
of nitric oxide, we next examined whether sinomenine has
any effect on the production of NO. The level of NO was
measured indirectly by the amount of nitrite present in
the culture medium [26]. Consistent with previous studies
[27,28], we found that treatment of BV2 cells with ADDL
led to a significant increase in the level of NO. However,
sinomenine reduced NO level (Figure 2). Thus, sinome-
nine inhibits ADDL-induced enhancement of NO level in
BV2 cells.
The cellular morphology of some of the cultures used
for ROS and NO assays was also examined. ADDL-treated
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Figure 1 Pre-treatment, but not simultaneous treatment, of sinomenine inhibits oligomeric Ab (ADDL)-induced increase in level of
reactive oxygen species (ROS) in microglial BV2 cells. ROS levels were determined using the DCFDA reagent. A. BV2 cells were pre-treated
with different concentrations of sinomenine before addition of ADDL. ADDL significantly increased the level of ROS in BV2 cells. However, pre-
treatment with sinomenine inhibited ADDL-induced increase in ROS level (n = 6 in all groups). B. BV2 cells were either pre-treated with
sinomenine before ADDL addition (Sinomenine pre-treatment) or treated with sinomenine and ADDL simultaneously (Simultaneous addition).
Whereas pre-treatment of sinomenine inhibited ADDL-induced ROS generation, simultaneous treatment of sinomenine had no effect on ADDL-
induced ROS level (n = 7 in all groups). There was no significant difference between ADDL and ADDL + sinomenine groups when simultaneous
addition was performed. In Figures 1A, 2, 5, 6 and 8, the effects of sinomenine alone were also examined. Compared to control, sinomenine
alone had no significant effects. Asterisks denote significant differences (p < 0.05).
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morphology. Sinomenine reduced the effects of ADDL on
morphological changes in BV2 cells (Figure 3).
Sinomenine reduces A-beta-induced increases in
inflammatory molecules
Treatment of microglial cells with Ab has previously
been shown to increase the levels of inflammatory mole-
cules [26,29,30]. Thus, we examined whether sinomenine
has any effects on oligomeric Ab-induced release of cyto-
kines and chemokine from BV2 cells. Cell-free culture
medium, after treatment of BV2 cells with ADDL for
12 h in the presence or absence of sinomenine, was used
to assay levels of IL-6, IL-10, IL-12, TNF-a,I F N - g and
MCP-1. Statistically significant increases in levels of IL-6,
TNF-a, MCP-1 and IL-12 were observed following treat-
ment with ADDL. Treatment with sinomenine reduced
the levels of TNF-a and MCP-1 (Figure 4). Sinomenine
reduced the level of ADDL-induced IL-6, although this
was not statistically significant (p < 0.061). Although
sinomenine was effective in reducing ADDL-induced
increases in levels of inflammatory molecules, the levels
of these molecules were still more than the levels in con-
trol cultures. These results are consistent with the find-
ings of Qian and colleagues [15] who found that
sinomenine did not completely block LPS-induced
increases in TNF-a in microglial cells. Sinomenine did
not affect ADDL-induced increase in level of IL-12 (fold
control, ADDL = 1.39 ± 0.15; ADDL + sinomenine =
1.27 ± 0.11, p > 0.26 compared to ADDL; n = 7 in all
groups). ADDL did not significantly affect the levels of
IFN-g or IL-10, and sinomenine did not affect the levels
of these molecules (fold control, IFN-g,A D D L=1 . 1±
0.16, p > 0.6 compared to control; ADDL + sinomenine =
1.16 ± 0.08, p > 0.43 compared to ADDL; IL-10, ADDL =
1.28 ± 0.2, p > 0.30 compared to control; ADDL + sino-
menine = 1.16 ± 0.12, p > 0.45 compared to ADDL; n = 7
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Figure 2 Sinomenine inhibits Ab-induced increase in the level
of nitric oxide (NO) in BV2 cells. BV2 cells were treated with
oligomeric Ab (ADDL) in the presence or absence of sinomenine.
NO release was estimated using the Griess reagent. ADDL treatment
of BV2 cells increased the level of NO, but sinomenine inhibited the
effect of ADDL on NO level (n = 7 in all groups). Asterisks denote
significant differences (p < 0.05).
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Figure 3 Sinomenine inhibits morphological changes induced
by oligomeric amyloid-b. Phase contrast images (20×
magnification) of BV2 cells treated with oligomeric Ab (ADDL) in the
presence or absence of sinomenine show that ADDL treatment led
to extended processes and elongated morphology of the cells, but
sinomenine reduced these ADDL-induced morphological changes.
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menine reduces oligomeric Ab-induced release of inflam-
matory and toxic substances.
Sinomenine confers protection to hippocampal HT22 cells
against indirect toxicity
As noted earlier, activated microglial cells release sub-
stances that can cause toxicity to neurons. This indirect
toxicity could also play important roles in the develop-
ment of neurodegenerative diseases including AD. Since
we found that sinomenine inhibits ADDL-induced pro-
d u c t i o no fi n f l a m m a t o r ya n dt o x i cm o l e c u l e s ,w en e x t
asked whether it affects indirect toxicity to hippocampal
cells. For this purpose, we used a hippocampal cell line,
HT22 that has been used in previous studies to examine
toxicity by different agents, including Ab [31-34]. We first
used an MTT reduction assay to examine the effect of
sinomenine on ADDL-induced indirect toxicity to HT22
cells. We found that when HT22 cells were treated with
conditioned medium from ADDL-treated BV2 cells, there
was a significant decrease in cell viability. However, when
the cells were treated with conditioned medium from BV2
cells treated with ADDL and sinomenine, the cell viability
was close to that of control cultures (Figure 5A). Thus,
sinomenine protects HT22 cells against indirect toxicity
induced by ADDL.
We used another measure, TUNEL assay, to examine
the protective effect of sinomenine against indirect neu-
rotoxicity. This assay is based on labeling of fragmented
DNA during cell death. In this assay also, we found that
treatment of HT22 cells with conditioned medium from
ADDL-treated BV2 cells led to significant toxicity as evi-
dent by increased number of cells that were positive for
TUNEL staining. In contrast, conditioned medium from
ADDL plus sinomenine-treated BV2 cells did not
increase the number of TUNEL-positive cells (Figure
5B). These results suggest that the neuronal toxicity was
mediated by factors released from the microglial cells
after treatment with ADDL, and that sinomenine con-
fers protection to HT22 cells against indirect toxicity by
oligomeric Ab.
Sinomenine confers protection to primary hippocampal
cells against indirect toxicity
Having shown that sinomenine protects HT22 cells
against indirect toxicity induced by Ab,w en e x ta s k e d
whether it has any effect on indirect toxicity to primary
hippocampal cells. For these experiments, we again used
TUNEL staining. We found that treatment of primary
hippocampal cells with conditioned medium from
ADDL-treated BV2 cells led to a significant increase in
the number of TUNEL-positive cells. However, treatment
with conditioned medium from ADDL plus sinomenine-
treated BV2 cells showed reduced number of TUNEL-
positive cells (Figure 6). Thus, sinomenine also protects
primary hippocampal cells from indirect toxicity by oli-
gomeric Ab.
Since the conditioned medium of BV2 cells treated
with oligomeric Ab was toxic to HT22 and primary hip-
pocampal cells, it was of interest to determine if the
conditioned medium contained higher levels of toxic
molecules, and whether the levels of these molecules
were affected by sinomenine. For these experiments,
BV2 cells were treated with oligomeric Ab for 6 h with
or without sinomenine. The medium was then replaced
with fresh medium without Ab and sinomenine, and
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Figure 4 Sinomenine reduces Ab-induced increases in inflammatory molecules. BV2 cells were treated with oligomeric Ab (ADDL) in the
presence or absence of sinomenine and levels of inflammatory molecules were determined using flow cytometry. Treatment with ADDL led to
an increase in levels of TNF-a, IL-6 and MCP-1. However, treatment with sinomenine decreased levels of inflammatory molecules (n = 7 for
TNF-a and IL-6, n = 4 for MCP-1). *, p < 0.05 and #, p < 0.061.
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Figure 5 Sinomenine inhibits Ab-induced indirect toxicity to HT22 cells. A. An MTT reduction assay shows that conditioned medium from
ADDL-treated BV2 cells reduces the viability of HT22 cells. However, the decrease in cell viability was ameliorated by sinomenine (n = 4 in all
groups). B. TUNEL assay shows that sinomenine prevents indirect toxicity to HT22 cells. Sample images (B1) and quantified summary data (B2) of
DAPI- or TUNEL-stained HT22 cells treated with different conditioned media show that conditioned medium from ADDL-treated BV2 cells
significantly increased the number of TUNEL-stained cells. However, conditioned medium from ADDL + sinomenine-treated BV2 cells did not
increase the number of TUNEL positive cells (n = 4 in all groups). Asterisks denote significant differences (p < 0.05). Scale bar, 100 μm.
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Figure 6 Sinomenine inhibits Ab-induced indirect toxicity to primary hippocampal cells.( A )S a m p l ei m a g e so fD A P I -o rT U N E L - s t a i n e d
primary hippocampal cells treated with BV2-conditioned media as indicated. Scale bar, 100 μm. (B) Quantified summary data show that
conditioned medium from ADDL-treated BV2 cells significantly increased the number of TUNEL-positive cells. However, the number of TUNEL-
positive cells was not increased when the cells were treated with conditioned medium from ADDL plus sinomenine-treated BV2 cells (n = 3 in
all groups). Asterisks denote significant differences (p < 0.05).
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conditions as used for the collection of conditioned
media for the indirect neurotoxicity experiments
described above). The conditioned media were then
assayed for NO and inflammatory molecules. We found
increased levels of NO, IL-6, TNF-a and MCP-1 in the
ADDL-treated BV2-conditioned medium. However, the
levels of these molecules were reduced in conditioned
medium from BV2 cells treated with ADDL and sinome-
nine (Figure 7). ADDL did not significantly affect levels
of IFN-g, IL-10 and IL-12; and sinomenine did not affect
the level of these molecules (fold control, IFN-g, ADDL =
1.25 ± 0.29, p > 0.52 compared to control; ADDL + sino-
menine = 1.13 ± 0.15, p > 0.61 compared to ADDL; IL-
10, ADDL = 1.22 ± 0.15, p > 0.27 compared to control;
ADDL + sinomenine = 1.10 ± 0.10, p > 0.54 compared to
ADDL; IL-12, ADDL = 1.13 ± 0.13, p > 0.55 compared to
control; ADDL + sinomenine = 1.03 ± 0.13, p > 0.32
compared to ADDL, n = 8 in all groups). These results
show that ADDL increased levels of NO and inflamma-
tory molecules in BV2-conditioned medium, but sinome-
nine reduced their levels.
Sinomenine does not confer protection to hippocampal
cells against direct toxicity
Having shown that sinomenine protects hippocampal
cells against ADDL-induced indirect toxicity, we next
asked whether this compound has any protective effect
against direct A-beta toxicity. We found that treatment
of HT22 cells with ADDL led to significant reduction in
viability as assessed by MTT reduction assay. However,
sinomenine did not affect ADDL-induced reduction in
HT22 cell viability (Figure 8A). In the TUNEL assay
also, we found that ADDL treatment increased the num-
ber of TUNEL-positive cells, and that this effect was not
affected by sinomenine (Figure 8B). Thus, while sinome-
nine has protective effects against indirect neurotoxicity
induced by A-beta, it does not show protection against
direct toxicity.
Discussion
In this study, we show that sinomenine, an alkaloid from
a Chinese medicinal plant, inhibits oligomeric Ab-
induced increases in levels of ROS, NO and inflammatory
molecules. In addition, sinomenine confers protection to
hippocampal cells (HT22) against indirect toxicity.
Furthermore, sinomenine also protects primary hippo-
campal cells from indirect toxicity.
Considerable evidence points to an important role for
Ab in the pathogenesis of AD. With regards to neuro-
toxicity, Ab can directly cause neuronal cell death
(direct toxicity) or Ab can affect microglial cells to pro-
duce inflammatory and toxic factors that then affect the
viability of neurons. The second mode of neuronal toxi-
city is referred to as indirect toxicity. Both kinds of
toxicity mechanisms have been described in the litera-
ture. Microglia are the brain’s resident immune cells
that offer defense against pathogens. These cells are
associated with the amyloid plaques in the brains of
both human AD patients and AD transgenic animals
[10]. Microglia-mediated inflammation has been impli-
cated in the pathogenesis of neurodegenerative disor-
ders including AD [11,35]. Thus, while microglial
function is important for normal functioning of the
brain, over-activation of microglia could have deleter-
ious effects [10,12].
ADDL + 
Sinomenine
N
O
 
(
%
 
 
c
o
n
t
r
o
l
)
50
100
150
Control ADDL
75
125
175
**
I
L
-
6
 
(
f
o
l
d
 
c
o
n
t
r
o
l
)
0.5
1.0 
1.25
Control ADDL
0.75
* *
ADDL + 
Sinomenine
M
C
P
-
1
 
(
f
o
l
d
 
c
o
n
t
r
o
l
)
ADDL + 
Sinomenine
0.5
1.0 
0.75
Control ADDL
1.25
* *
ADDL + 
Sinomenine
T
N
F
-
Į
(
f
o
l
d
 
c
o
n
t
r
o
l
)
0.5
1.0
1.5
Control ADDL
0.75
1.25
**
Figure 7 Levels of nitric oxide and inflammatory molecules in BV2-conditioned media. The levels of nitric oxide (NO) and inflammatory
molecules in BV2-conditioned media prepared similarly to the conditioned media used for indirect toxicity experiments, were assayed using Griess
reagent and flow cytometry, respectively. Oligomeric Ab (ADDL) increased levels of NO (n = 4 in all groups), TNF-a, IL-6 and MCP-1 (n = 8 in all
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Page 8 of 11Ab induces ROS generation in microglial cells [36]. In
addition, Ab induces the production of NO in these cells
[26-28]. Reactive oxygen species and nitric oxide have
been implicated in the pathogenesis of AD. The analysis
of AD brain samples reveals evidence of ROS and NO
production [10]. In addition, Ab activates microglia lead-
ing to the release of inflammatory molecules [26]. An
enhancement in cytokine levels is observed in AD trans-
genic animals [37,38]. Collectively, several studies suggest
that Ab activates microglia which may contribute to AD
pathology by promoting inflammation and neuronal toxi-
city. We found that sinomenine inhibits ADDL-induced
production of ROS, NO and inflammatory molecules.
Importantly, we also showed that sinomenine confers
protection against indirect toxicity to hippocampal cells.
Our results are consistent with the study of Wang et al
[16], who showed that sinomenine inhibits advanced gly-
cation end products-induced release of cytokines, and
enhancement of ROS production, in retinal microglial
cells. In addition, Qian and colleagues showed that sino-
menine inhibits LPS-induced NO and ROS production
[15]. These authors showed also that sinomenine confers
protection to dopaminergic neurons against LPS- and
MPP+-induced toxicity in neuron-glia cultures.
Although sinomenine was effective in reducing indir-
ect toxicity, it did not confer protection to hippocampal
HT22 cells in direct toxicity experiments. This finding is
consistent with that of Qian et al [15] who showed that
although sinomenine protects dopaminergic neurons
against MPP+-induced toxicity in neuron-glia cultures,
it has no effects in neuron-enriched cultures.
Since inhibition of microglia-mediated damage could
be helpful in at least delaying the progression of AD,
anti-inflammatory therapy is considered a promising
strategy in this disease. It has been shown that intraperi-
toneally injected or orally administered sinomenine can
reach the brain [39,40] suggesting that it can cross blood-
brain barrier. In addition, intraperitoneally injected sino-
menine confers protection in ischemic brain injury [41].
It would be interesting to examine whether sinomenine
reduces inflammation and confers neuroprotection in
vivo in a model of Alzheimer’s disease. Since sinomenine
does not confer protection against Ab-induced direct
neuronal toxicity, the protection observed would likely be
due to its effects on microglia. Our results, along with
those of other studies, suggest that sinomenine may have
therapeutic potential in neurodegenerative diseases that
involve neuroinflammation.
Conclusions
Our results show that sinomenine inhibits oligomeric
amyloid-b-induced increases in levels of ROS, NO and
inflammatory molecules in BV2 microglial cells. More-
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Page 9 of 11primary hippocampal cells from indirect toxicity
mediated by amyloid-b-treated BV2 cells. Thus, sinome-
n i n em a yh a v et h e r a p e u t i cv a l u ei nn e u r o d e g e n e r a t i v e
diseases, including Alzheimer’s disease.
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